Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | ALPI | P09923 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | XIAP | P98170 | 1/20 | 0.60 |
| ▸ | NOS3 | P29474 | 3/20 | 0.58 |
| ▸ | NOS1 | P29475 | 3/20 | 0.58 |
| ▸ | NOS2 | P35228 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KYNU | Q16719 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29701247 | 1.00 | SLC7A5 (0.60) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL385780 | 1.00 | SLC7A5 (0.60) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL288832 | 1.00 | SLC7A5 (0.60) | SLC7A5PKMALPIPTGS1XIAP | |
| Phenylalanine SCHEMBL16397405 | 0.93 | SLC7A5 (0.73) | SLC7A5PKMALPIPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL16397404 | 0.93 | SLC7A5 (0.73) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL13971424 | 0.88 | SLC7A5 (0.69) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL9164980 | 0.88 | SLC7A5 (0.69) | SLC7A5PKMALPIPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL9169793 | 0.86 | SLC7A5 (0.67) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL13703210 | 0.85 | PKM (0.52) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL10886402 | 0.83 | NOS3 (0.41) | SLC7A5PKMALPIPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AMBRX, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12404512-B2 | Method for optimizing antibody expression | AMBRX, INC. (US) | 2025-09-02 | — | — | US | claimed |
| EP-3788149-B1 | A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION | AMBRX INC (US) | 2025-08-27 | — | — | EP | claimed |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | AMBRX, INC. (US) | 2025-08-05 | — | — | US | claimed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | claimed |
| EP-4461318-A2 | NOVEL ANTI-PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | Ambrx, Inc. (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240350835-A1 | HUMANIZED ANTI-PROSTATE -SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | AMBRX, INC. (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024178360-A2 | AURISTATIN ANALOGS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| US-12059473-B2 | Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates | AMBRX, INC. (US) | 2024-08-13 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| EP-1991572-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | claimed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | SLC7A5 1600/4885PKM 2553/4885ALPI 2014/4885 |
| US-12059473-B2 | Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates | FOLH1, KLK3, PSMA6 | SLC7A5 1731/4885PKM 1370/4885ALPI 249/4885 |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | FOLR2, FOLR1, CD2 | SLC7A5 271/4885PKM 4371/4885ALPI 1217/4885 |
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AARS1, NSUN3, UPF1 | SLC7A5 136/4885PKM 2865/4885ALPI 2459/4885 |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | SLC7A5 1904/4885PKM 4767/4885ALPI 3829/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | SLC7A5 1849/4885PKM 1346/4885ALPI 2376/4885 |
| US-20240350835-A1 | HUMANIZED ANTI-PROSTATE -SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | FOLH1, KLK3, PSMA6 | SLC7A5 1803/4885PKM 1423/4885ALPI 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.